Clinical Trial Update: Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial of ramucirumab or IMC-3G3 (anti-PDGFR alpha antibody) in recurrent glioblastoma multiforme has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• IMC-3G3
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Adult Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2017-03-29